AstraZeneca Stock News

After years of strong returns, amidst the tariff-induced uncertainty, I am rotating towards European-based equities. US economy is facing mounting pressures, via weakening consumer demand, reduced CAPEX spending, inflation, and rising recession odds. European equities are relatively cheap, and despite structural issues, pockets of opportunities exist in high-growth areas and via re-arming Europ...

Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, demanded help to maintain operations in the EU despite threatened U.S. tariffs on imports, including measures to compensate them for the cost of pharmaceutical innovations, French business newspaper Les Echos reported on Tuesday.

U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.

Over the previous seven trading sessions -- i.e., since President Donald Trump announced his "Liberation Day" tariffs -- Wall Street has experienced some of the wildest volatility since the COVID-19 crash in February-March 2020.

President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC.  The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.

The Company spend billions to produce 100% of its key medicines for Americans in the U.S.

AstraZeneca PLC (LSE:AZN) is due to report first-quarter earnings on April 29, and UBS is bracing for a modest miss against market expectations, though the bank maintains a broadly supportive stance on the UK-listed drugmaker. Analysts at the Swiss investment bank expect group revenue and core operating profit to come in around 1% and 2% below Visible Alpha consensus, respectively, with softer-...

UBS has warned that drugmakers such as AstraZeneca and GSK could be among the most exposed in Europe's pharmaceuticals sector should President Trump follow through on threats to impose new levies on the industry, despite medicine currently being exempt from trade tariffs. In a detailed report analysing potential flashpoints for investors, the Swiss bank argues that while the European sector as ...